Evidence map›Paper›PMID 40916366›Full record

ArticleRenal failure2025

Management of rituximab in patients with PLA2R-associated membranous nephropathy of different age: a single-center retrospective cohort study.

Xueting Li, Lei Song, Le Wang, Ben Ke, Wen Shen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xueting LiDepartment of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Lei SongDepartment of General Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Le WangDepartment of Blood Transfusion, The Second Affiliated Hospital to Nanchang University, Nanchang, China.
Ben KeDepartment of Nephrology, The Second Affiliated Hospital of Nanchang University, Jiangxi Province Key Laboratory of Immunology and Inflammation, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Wen ShenDepartment of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRituximab (RTX) has become the first-line therapy for idiopathic membranous nephropathy (IMN). The safety of low-dose and long-course RTX regimen in elderly patients with IMN remains unknown.

methodsSixty-nine IMN patients with anti-M-phospholipase A2 receptor (PLA2R) antibodies-positive were recruited for this study. The patients were categorized into two groups based on their age. The different age groups were further divided into the recommended RTX group and the low-dose and long-course RTX group. Compare the outcomes and adverse events of patients between different groups after 9-month follow-up.

resultsThere was no significant difference in the complete remission rate and composite remission rate in patients with IMN in different age who received different RTX regimens. As expected, the risk of adverse events was higher in the recommended-dose RTX group compared with the low-dose and long-course RTX group in patients with IMN aged ≥60 years (66.7% vs. 19%,

conclusionsThe low-dose and long-course RTX regimen should be recommended for elderly patients with IMN, and the percentage of eosinophilic granulocytes is a better risk predictor of infections after RTX used in elderly patients with IMN.

Indexed as

Glomerulonephritis, MembranousImmunologic FactorsReceptors, Phospholipase A2RituximabAdultAgedAge FactorsFemaleHumansMaleMiddle AgedRemission InductionRetrospective StudiesRisk FactorsTreatment OutcomeImmunologic FactorsPLA2R1 protein, humanReceptors, Phospholipase A2Rituximabeosinophilic granulocytesIdiopathic membranous nephropathyinfectionlow-dose and long-course rituximab regimenolder

Identifiers

PMID40916366
PMCPMC12418790

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.